机器人多支内镜冠脉搭桥:心脏不停跳与连接器的应用效果
该研究回顾性比较了机器人心脏不停跳下使用远端吻合连接器行多支与单支全内镜冠状动脉搭桥(TECAB)的安全性和疗效。多支组197例,单支组147例。结果显示两组在死亡率、住院时间、中期主要不良心脏事件和移植物通畅率上均无显著差异,多支TECAB可行且效果良好。
要点
- 机器人心脏不停跳使用连接器行多支TECAB可行,安全性与单支TECAB相当。
- 多支组88%使用双侧乳内动脉桥,13%完成三支TECAB。
- 两组移植物通畅率(平均7个月)分别为95.6%和94.9%,无显著差异。
核心结论
- 机器人心脏不停跳使用远端吻合连接器行多支TECAB可行且效果良好。
- 与单支TECAB相比,多支TECAB在死亡率、住院时间、中期主要不良心脏事件和移植物通畅率上无显著差异。
研究设计与样本
- 回顾性队列研究,纳入2013年7月至2018年3月期间在本机构接受机器人TECAB的344例连续患者。
- 分为多支组(197例)和单支组(147例),比较术前、术中和术后结局。
主要发现
- 多支组平均STS评分为1.69%±2.4%,单支组为1.96%±3.5%(p=0.389)。
- 多支组年龄更大(67±9.4岁 vs 63±11.2岁,p<0.001),三支病变比例更高(135例(69%) vs 31例(21%),p<0.001)。
- 多支组174例(88%)使用双侧乳内动脉桥,13%完成三支TECAB。
- 平均住院时间多支组3.07±1.2天,单支组2.81±1.4天(p=0.072)。
- 总体死亡率1.45%(多支组2.0%,单支组0.7%;p=0.268)。
临床怎么用
- 对于适合的患者,机器人心脏不停跳使用连接器行多支TECAB是可行的,且未增加死亡、住院时间、中期主要不良心脏事件或移植物通畅率的风险。
局限性
- 需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most robotic coronary bypass operations are single-vessel procedures. Very few centers perform totally endoscopic coronary artery bypass (TECAB), and even fewer perform multivessel grafting endoscopically. We hypothesized that a robotic beating-heart approach using distal anastomotic connectors facilitates multivessel TECAB with similar safety and efficacy to single-vessel TECAB. METHODS: We reviewed patients undergoing robotic TECAB at our institution between July 2013 and March 2018. There were 344 consecutive patients divided into two groups: multivessel (MV, group 1), and single-vessel (SV, group 2). We interrogated our prospectively collected database for preoperative, intraoperative, and postoperative outcomes to compare the groups. RESULTS: There were 197 patients in group 1 and 147 patients in group 2. Mean Society of Thoracic Surgeons scores were 1.69% ± 2.4% and 1.96% ± 3.5%, respectively (p = 0.389). Patients in group 1 were older, 67 ± 9.4 versus 63 ± 11.2 years (p < 0.001) and had more triple-vessel disease, 135 (69%) versus 31 (21%; p < 0.001). In group 1, 174 patients (88%) had bilateral internal mammary artery grafts and 13% had triple-vessel TECAB. Mean hospital stay was 3.07 ± 1.2 days in group 1 and 2.81 ± 1.4 days in group 2 (p = 0.072), and overall mortality was 1.45% (2.0% and 0.7%, respectively; p = 0.268). Graft patency (mean, 7 months) was 95.6% (151 of 158 grafts) in group 1 and 94.9% (37 of 39 grafts) in group 2 (p = 0.896). CONCLUSIONS: Multivessel grafting is feasible during robotic beating-heart connector TECAB with good outcomes. We found no significant difference in mortality, hospital stay, midterm major adverse cardiac events, and interim graft patency compared with single-vessel TECAB. Further studies are warranted.
引用
- Balkhy HH, Nisivaco S, Kitahara H, et al. Robotic Multivessel Endoscopic Coronary Bypass: Impact of a Beating-Heart Approach With Connectors. Ann Thorac Surg. 2019. PMID: 30690021. doi:10.1016/j.athoracsur.2018.12.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。